DyAnsys Blog

San Mateo, Ca – Patients going through the difficult opioid withdrawal process are often treated with other opioids to address the range of symptoms and reduce cravings. They now have another option with the FDA clearance of a small, wearable device developed by DyAnsys Inc.

 The device,...

At DyAnsys, patient safety is a primary concern and focus during product development as well as when products are in use. Chief Executive Officer Srini Nageshwar talked recently about the company's approach to patient safety as well as...

Primary Relief neurostimulator demonstration

When patients come in for a Primary Relief® treatment, they see a conveniently packaged system powered by a hand-held device that appears to be little more than a common mobile phone.

That deceptively small device offers a wide-range of...

DyAnsys Symposium

9th International Auriculotherapy Symposium Offers New Insights and Scientific Update

Insights from DyAnsys Chief Executive Srini Nageshwar 

In recent years, pioneers in...

ANSiStim

Health Care Leaders Call for Accelerated Research to End Opioid Crisis      

National Institutes of Health leaders took a remarkable step recently in calling for an “all scientific hands on deck” to end the opioid crisis. They rightly identified a multi-pronged approach...